Milind Javle, MD
Enriched profileClinical Medical Director, Gastrointestinal Medical Oncology, and Hubert L. and Olive Stringer Professor of GI Medical Oncology, The University of Texas MD Anderson Cancer Center · The University of Texas MD Anderson Cancer Center
Milind Javle is Clinical Medical Director, Gastrointestinal Medical Oncology, and Hubert L. and Olive Stringer Professor of GI Medical Oncology, The University of Texas MD Anderson Cancer Center at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 735 publications with 22,987 citations (h-index 75); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Milind Javle, MD, is Clinical Medical Director, Gastrointestinal Medical Oncology, and Hubert L. and Olive Stringer Professor of GI Medical Oncology, The University of Texas MD Anderson Cancer Center. The public record shows 735 publications with 22,987 citations (h-index 75), centered on Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 21 companies, 1 NIH-funded awards (2009–2011).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cholangiocarcinoma and Gallbladder Cancer Studies
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 270.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Sponsor: TransThera Sciences (Nanjing), Inc.
- Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Sponsor: TransThera Sciences (Nanjing), Inc.
- Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- TAIHO ONCOLOGY, INC.Program year20254 payments
- Delcath SystemsProgram year20251 payment
- AstraZeneca UK LimitedProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
41.7%Serotonin-3 Receptor Antagonist23.5%Ondansetron Hcl100%Part D≥24 patientsAntidiarrheal microorganisms9.8%Creon100%Part D<11 patientsNervous system
19.7%Phenothiazine19.7%Prochlorperazine Maleate100%Part D≥22 patientsBlood & clotting
16.7%Factor Xa inhibitor16.7%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2009–2011 per NIH RePORTER. The latest:
- Phase I Study of the BikDD Nanoparticle for Advanced Cancer of the Pancreas
University of Tx Md Anderson Can Ctr
FY2011$328,636R21CA135604 - Phase I Study of the BikDD Nanoparticle for Advanced Cancer of the Pancreas
University of Tx Md Anderson Can Ctr
FY2009$338,800R21CA135604
Congress activity
Updated 27 Aug 2026
228 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Biomarker study of BND-22 in combination with cemiplimab in solid tumors.
ASCO Annual Meeting
ASCO2026Co-author - Abstract 1121: Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE database
AACR Annual Meeting
AACR2025Co-author - Abstract 4352: Safety and pharmacokinetics of tinengotinib monotherapy in different doses and dosing schedules in advanced solid tumors
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.
Clinical cancer research
Article2026 - Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy.
Journal of clinical oncology
Letter2026 - ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.
JCO precision oncology
Article2026 - Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaArticle719 citations2017
- 03
- 04
- 05Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersArticle476 citations2019
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/milind-javle-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/milind-javle-257b6223a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Milind-Javle-38504257
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/BALCOMedical/videos/dr-milind-javle-md-anderson-cancer-centre-and-priyanka-joshi-founder-of-jarurat-/779996674983937
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Facebook
facebook.com/TheASCOPost/videos/milind-m-javle-md-on-cholangiocarcinoma-treatment-with-infigratinib/128077629159326
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- Irwin H. Krakoff Award for Excellence in Clinical Research
The University of Texas MD Anderson Cancer Center
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ccanewsonline.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Contributing expert author
OncLive (video interviews and written commentary on biliary tract/GI cancers)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center